Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3552W HIGH $3.42
Volume
100.00
Value Traded
30.00
Short % Float
0.08%
-21.74%Week
-56.63%1 Month
-85.03%3 Month
-85.88%6 Month
-95.12%5 Year
-95.12%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.68 M
EPS (TTM)
-0.19
P/E Ratio
-
Ent. Value
5.64 M
Total Shares
41.02 M
Float Shares
7.26 M
Insiders
40.54%
Institutions
54.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ANEB Catalyst Timeline
Dated clinical, regulatory and corporate events for Anebulo Pharmaceuticals, Inc.
Past FDA Catalysts and PDUFA Decisions
How ANEB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ANEB-001 Small moleculeCompletedNCT05282797 | Acute Cannabinoid Intoxication | Phase 2 | COMPLETED | 154 | Aug 26, 2023 | ||||||
| selonabant Small moleculeCompletedNCT07211607 | Undisclosed | Phase 1 | COMPLETED | 40 | May 6, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ANEB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| English Aron R.Director, 10% Owner | BuyOffering | 10,101,010 15,467,300 held | $0.99 | 12/23/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in ANEB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 17.91 K | 17.74 K | -88.75% ( -139.98 K) |
Ownership Trends
ANEB Short Interest
Shares sold short, counted twice a month.
0.08%
Short % of Float
of tradable shares sold short
390.8K
Shares Sold Short
0.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
186
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANEB ranks across every disease it competes in
Competitive Position is a premium feature
See how ANEB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANEB News
About Anebulo Pharmaceuticals, Inc.
HeadquartersLakeway
Founded2020
BIOPHARMAWATCH ELITE PLUS
Trade the next ANEB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime